​​Exocrine Pancreatic Insufficiency​ research hub

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.

This study looks at a new medicine, NHS7108, for people with Exocrine Pancreatic Insufficiency (EPI). It compares NHS7108 to an existing medicine, Zenpep, to see how safe and effective different doses are in helping the body digest food.